ABSTRACT
Introduction In 2022 the WHO declared the worldwide outbreak of mpox to be a public health emergency of international concern (PHEIC). The causative monkeypox virus (MPXV) belonged to Clade IIb and transmitted through sexual contact with a low case fatality rate (0.1%), which together with underdetection, all contributed to a rapid global spread particularly within the MSM (men who have sex with men) community. As MPXV Clade II remains circulating worldwide, a new outbreak of the more fatal Clade I disease has been declared in Central and East Africa and remains uncontrolled in part due to the lack of Point of Care (POC) diagnostics for rapid decisions on treatment and self-isolation.
Aim To address the lack of POC solutions for mpox we have designed and evaluated an orthopoxvirus-specific lateral flow device (LFD) that could be used for diagnosis of mpox.
Results Using an LFD comprising four monoclonal antibodies against the A27 protein we demonstrate sensitivity to 3×105 pfu/ml. This sensitivity is expected to be sufficient for detection of MPXV from lesion sites and may also be sufficient for other sample types such as saliva and urine. However, sample collection buffer may have a detrimental impact on sensitivity for clinical material.
Conclusion Point of care (POC) diagnosis of mpox may be possible using a LFD to reduce delays arising from sample shipment to centralised laboratory testing facilities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by BBSRC, US FDA, DSTL and the Pandemic Sciences Institute AZ grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript